Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease.
Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease.
Five Alarm Bio, a UK drug discovery startup focussing on the underlying mechanisms of ageing to develop therapeutics for age-related disease, works with Magnitude Biosciences to test their compound, FAB001, to test their hypothesis on the nature of ageing.
David Weinkove, CEO of Magnitude Biosciences joins New Matter
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing researcher and entrepreneur David Weinkove, Associate Professor at the Department of Biosciences, Durham University and CEO of Magnitude Biosciences Ltd.
Michelin, a Fortune 500 consumer good manufacturing company and the global leader in tyre manufacturing, works with Magnitude Biosciences for a sustainable, ethical solution for whole organism toxicity testing.
Take a look at our Poster from ELRIG Drug Discovery 2021: Automated Monitoring of C. elegans Movement for Neurodegeneration and Ageing.